Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $63.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.41M
Average 0.43M
FBIO Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Fortress Biotech, Inc.NASDAQ: FBIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $110.37M, compared with -$24.69M a year earlier. Trailing-twelve-month net income was $102.15M. Over 3 fiscal years it compounded at -46.4% a year.
Context
- Net income amounted to 52.0% of revenue in FY2025, down 157.5 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $93.15M (+383.0%) for the fiscal year ending Dec 2026, a step up from the -72.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $110.37M+2145.1% QoQ
- Last fiscal yearDec 2025
- -$32.92M-72.8% YoY
- LTMMar 2026
- $102.15M+215.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +547.0% | -42.1% | -589.1 pp |
| 1 year | -72.8% | +383.0% | +455.8 pp |
| 3-year CAGR | -46.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (32.92M) USD
- Year-over-year change
- +72.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32.92M) | +72.8% |
| FY2024 | 2024-12-31 | (120.86M) | +21.6% |
| FY2023 | 2023-12-31 | (154.15M) | +27.9% |
| FY2022 | 2022-12-31 | (213.91M) | -29.8% |
| FY2021 | 2021-12-31 | (164.83M) | — |
Net Income vs competitors
How FBIO compares with its peers on the latest reported figures
- FBIO's LTM Mar 2026 net income of $102.15M is the 3rd largest of the 10 companies compared; the peer median is $40.16M.
- Its year-over-year change of +215.2% is the highest of 9, against a peer median of +1.7%.
- Net income amounts to 154.4% of revenue for FBIO, versus a peer median of 904.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $40.16M | +1.9% | +11.4% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| LTM Jun 2024 | $31.85M | — | -39.6% | 3904.3% | |
| LTM Mar 2026 | $21.24M | +1.5% | +4.7% | — | |
| LTM Apr 2026 | $8.08M | -19.0% | +22.4% | 448.4% | |
| Peer median (excluding FBIO) | $40.16M | +1.7% | +3.3% | 904.5% | |
Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (164.83M) | (213.91M) | (154.15M) | (120.86M) | (32.92M) |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 19.49M | 22.99M | 17.03M | 32.62M | 28.74M |
| Change in Working Capital | 36.37M | (715K) | (12.52M) | (8.13M) | (25.1M) |
| Accounts Receivables | 834K | (4.84M) | 12.52M | 4.47M | (19.33M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 43.31M | 8.35M | (24.38M) | (6.39M) | (7.97M) |
| Other Working Capital | 690K | (5.97M) | (4.61M) | (1.98M) | (2.6M) |
| Other Non-Cash Items | (14.36M) | 2.89M | 15.42M | 11.71M | (41.17M) |
| Operating Cash Flow | (116.54M) | (179.4M) | (128.23M) | (80.19M) | (65.78M) |
| Capital Expenditures | (16.35M) | (3.06M) | (8.1M) | (15M) | 0 |
| Acquisitions (Net) | 56.86M | (20M) | 0 | 0 | 8.96M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.78M) | (213K) | (2.04M) | 0 | 1.17M |
| Investing Cash Flow | 40.51M | (22.93M) | (2.1M) | (15M) | 10.12M |
| Debt Repayment | (9.64M) | 49.25M | (38.79M) | (7.33M) | (5.64M) |
| Common Stock Issued | 155.26M | 40.26M | 80.38M | 82.84M | 84.63M |
| Common Stock Repurchased | 0 | (1.11M) | 0 | 0 | (265K) |
| Dividends Paid | (8.78M) | (8.78M) | (8.77M) | (4.71M) | (664K) |
| Other Financing Activities | (4.8M) | (6.74M) | (529K) | (163K) | (360K) |
| Financing Cash Flow | 148.99M | 75.32M | 32.74M | 70.64M | 77.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 72.97M | (127.01M) | (97.59M) | (24.55M) | 21.79M |
| Free Cash Flow | (132.89M) | (182.46M) | (136.32M) | (95.19M) | (65.78M) |
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.